Treatment | CRP mRNA Levelsb | |
---|---|---|
Primary Human Hepatocytes | HepaRG Cells | |
None (control) | 1.0 ± 0.0 | 1.0 ± 0.0 |
Ruxolitinib | 0.2 ± 0.0 | 0.3 ± 0.2 |
IL-6 | 6223 ± 2667* | 1258 ± 125.7* |
Ruxolitinib/IL-6 | 0.2 ± 0.0§ | 0.3 ± 0.1§ |
↵* P < 0.05 when compared with control cells;
↵§ P < 0.05 when compared with IL-6-treated cells.
↵a Cells were either untreated (control), exposed to 5 μM ruxolitinib or 10 ng/ml IL-6, or coexposed to 5 μM ruxolitinib and 10 ng/ml IL-6 for 24 hours. CRP mRNA expression was then determined by reverse transcription-quantitative polymerase chain reaction.
↵b CRP mRNA levels are expressed comparatively to mRNA levels found in untreated control cells, arbitrarily set at 1 U; they are the means ± S.E.M. of values from six independent human hepatocyte populations or five HepaRG cell cultures.